1
|
Sabbagh C, Beyer-Berjot L, Ouaissi M, Zerbib P, Bridoux V, Manceau G, Karoui M, Panis Y, Buscail E, Venara A, Khaoudy I, Gaillard M, Ortega-Deballon P, Viennet M, Thobie A, Menahem B, Eveno C, Bonnel C, Mabrut JY, Badic B, Godet C, Eid Y, Duchalais E, Lakkis Z, Cotte E, Laforest A, Defourneaux V, Maggiorri L, Rebibo L, Christou N, Talal A, Mege D, Bonnamy C, Germain A, Mauvais F, Tresallet C, Ahmed O, Regimbeau JM, Roudie J, Laurent A, Trilling B, Bertrand M, Massalou D, Romain B, Tranchart H, Giger U, Dejardin O, Pellegrin A, Alves A. Risk factors for severe morbidity and definitive stoma after elective surgery for sigmoid diverticulitis: a multicenter national cohort study. Tech Coloproctol 2024; 28:34. [PMID: 38369674 DOI: 10.1007/s10151-023-02906-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 12/18/2023] [Indexed: 02/20/2024]
Abstract
BACKGROUND In the decision to perform elective surgery, it is of great interest to have data about the outcomes of surgery to individualize patients who could safely undergo sigmoid resection. The aim of this study was to provide information on the outcomes of elective sigmoid resection for sigmoid diverticular disease (SDD) at a national level. METHODS All consecutive patients who had elective surgery for SDD (2010-2021) were included in this retrospective, multicenter, cohort study. Patients were identified from institutional review board-approved databases in French member centers of the French Surgical Association. The endpoints of the study were the early and the long-term postoperative outcomes and an evaluation of the risk factors for 90-day severe postoperative morbidity and a definitive stoma after an elective sigmoidectomy for SDD. RESULTS In total, 4617 patients were included. The median [IQR] age was 61 [18.0;100] years, the mean ± SD body mass index (BMI) was 26.8 ± 4 kg/m2, and 2310 (50%) were men. The indications for surgery were complicated diverticulitis in 50% and smoldering diverticulitis in 47.4%. The procedures were performed laparoscopically for 88% and with an anastomosis for 83.8%. The severe complication rate on postoperative day 90 was 11.7%, with a risk of anastomotic leakage of 4.7%. The independent risk factors in multivariate analysis were an American Society of Anesthesiologists (ASA) score ≥ 3, an open approach, and perioperative blood transfusion. Age, perioperative blood transfusion, and Hartmann's procedure were the three independent risk factors for a permanent stoma. CONCLUSIONS This series provides a real-life picture of elective sigmoidectomy for SDD at a national level. TRIAL REGISTRATION Comité National Information et Liberté (CNIL) (n°920361).
Collapse
Affiliation(s)
- C Sabbagh
- Department of Digestive Surgery Service, Amiens University Hospital, Rond Point du Pr Cabrol, 80054, Amiens Cedex 01, France.
| | - L Beyer-Berjot
- Department of Digestive Surgery Assistance Publique Hôpitaux de Marseille, North University Hospital, Marseille, France
| | - M Ouaissi
- Department of Digestive, Oncological, Endocrine, Hepatobiliary and Liver Transplant, Trousseau Hospital, University Hospital of Tours, Tours, France
| | - P Zerbib
- Department of Digestive Surgery and Transplantation, Huriez Hospital, Universite Lille Nord de France, Lille, France
| | - V Bridoux
- Department of Digestive Surgery, University Hospital of Rouen, Rouen, France
| | - G Manceau
- Department of Surgery, European Georges Pompidou Hospital, AP-HP, Paris, France
| | - M Karoui
- Department of Surgery, European Georges Pompidou Hospital, AP-HP, Paris, France
| | - Y Panis
- Colorectal Surgery Center, Groupe Hospitalier Privé Ambroise Paré-Hartmann, Neuilly, France
| | - E Buscail
- Department of Surgery, CHU Toulouse-Rangueil and Toulouse University, Toulouse, France
| | - A Venara
- Department of Digestive Surgery, University Hospital of Angers, Angers, France
| | - I Khaoudy
- Department of Digestive Surgery, Le Havre Hospital, Le Havre, France
| | - M Gaillard
- Department of Digestive Surgery, Cochin Hospital, Paris, France
| | - P Ortega-Deballon
- Department of General Surgery, University Hospital of Bocage, Dijon, France
| | - M Viennet
- Department of General Surgery, University Hospital of Bocage, Dijon, France
| | - A Thobie
- Department of Digestive Surgery, Avranches-Granville Hospital, Avranches, France
| | - B Menahem
- Department of Digestive Surgery, University Hospital of Caen, Caen, France
| | - C Eveno
- Department of Digestive Surgery, University Hospital of Lille, Lille, France
| | - C Bonnel
- Department of Digestive Surgery, Nord-Essonne Hospital, Longjumeau, France
| | - J-Y Mabrut
- Department of Digestive Surgery and Transplantation, Croix Rousse University Hospital, Lyon, France
| | - B Badic
- Department of General and Digestive Surgery, University Hospital, Brest, France
| | - C Godet
- Department of Digestive Surgery, Memorial Hospital of Saint-Lô, Saint-Lô, France
| | - Y Eid
- Department of Digestive Surgery, Robert Bisson Hospital, Lisieux, France
| | - E Duchalais
- Department of Oncological, Digestive and Endocrine Surgery, University Hospital of Nantes, Nantes, France
| | - Z Lakkis
- Department of Digestive Surgical Oncology and Liver Transplantation, University Hospital of Besançon, Besançon, France
| | - E Cotte
- Department of Digestive Surgery, Hôpital Lyon Sud, Lyon, France
| | - A Laforest
- Department of Digestive Surgery, Montsouris Institut, Paris, France
| | - V Defourneaux
- Department of Digestive Surgery, CHU Rennes, Rennes, France
| | - L Maggiorri
- Department of Digestive Surgery, Hôpital Saint-Louis, Université Paris VII, APHP, Paris, France
| | - L Rebibo
- Department of Digestive, Oesogastric and Bariatric Surgery, Hôpital Bichat-Claude-Bernard, Paris, France
| | - N Christou
- Department of Digestive Surgery, Limoges Hospital, Limoges, France
| | - A Talal
- Department of Digestive Surgery, Argentan Hospital, Argentan, France
| | - D Mege
- Department of Digestive Surgery, Aix Marseille Univ, APHM, Timone University Hospital, Marseille, France
| | - C Bonnamy
- Department of Digestive Surgery, Bayeux Hospital, Bayeux, France
| | - A Germain
- Department of Digestive Surgery, CHRU Nancy, Nancy, France
| | - F Mauvais
- Department of Digestive Surgery, Beauvais Hospital, Beauvais, France
| | - C Tresallet
- Department of Digestive Surgical Oncology, Avicenne University Hospital, Paris, France
| | - O Ahmed
- Department of Digestive Surgical Oncology, Avicenne University Hospital, Paris, France
| | - J-M Regimbeau
- Department of Digestive Surgery Service, Amiens University Hospital, Rond Point du Pr Cabrol, 80054, Amiens Cedex 01, France
| | - J Roudie
- Department of Digestive Surgery, Martinique Hospital, Fort-de-France, France
| | - A Laurent
- Department of Digestive Surgery, Créteil Hospital, Créteil, France
| | - B Trilling
- Department of Digestive and Emergency Surgery, Grenoble Alpes University Hospital, Grenoble, France
| | - M Bertrand
- Department of Digestive Surgery, Universitary Hospital of Nîmes, Nîmes, France
| | - D Massalou
- Department of Digestive Surgery, Hôpital L'Archet, Nice University, Nice, France
| | - B Romain
- Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, Strasbourg, France
| | - H Tranchart
- Department of Minimally Invasive Digestive Surgery, Antoine Beclere Hospital, AP-HP, Clamart, France
| | - U Giger
- ANTICIPE, Inserm Unity, UMR 1086, Caen, France
| | - O Dejardin
- ANTICIPE, Inserm Unity, UMR 1086, Caen, France
- Department of Clinical Research, University Hospital of Caen, Caen, France
| | - A Pellegrin
- Department of Digestive Surgery Service, Amiens University Hospital, Rond Point du Pr Cabrol, 80054, Amiens Cedex 01, France
| | - A Alves
- Department of Digestive Surgery, University Hospital of Caen, Caen, France
| |
Collapse
|
2
|
Radhoe SP, Boersma E, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Brugts JJ. The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials. Cardiovasc Drugs Ther 2024; 38:131-139. [PMID: 36194352 PMCID: PMC10876738 DOI: 10.1007/s10557-022-07384-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/12/2022] [Indexed: 11/30/2022]
Abstract
PURPOSE To study the effects of a perindopril-based regimen on cardiovascular (CV) outcomes in patients with vascular disease in relation to background statin therapy. METHODS A pooled analysis of the randomized ADVANCE, EUROPA, and PROGRESS trials was performed to evaluate CV outcomes in 29,463 patients with vascular disease treated with perindopril-based regimens versus placebo. The primary endpoint was a composite of CV mortality, nonfatal myocardial infarction, and stroke. Multivariable Cox regression analyses were performed to assess the effects of a perindopril-based regimen versus placebo in relation to statin use. RESULTS At randomization, 39.5% of the overall combined study population used statins. After a mean follow-up of 4.0 years (SD 1.0), the cumulative event-free survival was highest in the statin/perindopril group and lowest in the no statin/placebo group (91.2% vs. 85.6%, respectively, log-rank p < 0.001). In statin users (adjusted hazard ratio [aHR] 0.87, 95% confidence interval [CI] 0.77-0.98) and non-statin users (aHR 0.80, 95% CI 0.74-0.87), a perindopril-based regimen was associated with a significantly lower risk of the primary endpoint when compared to placebo. The additional treatment effect appeared numerically greater in non-statin users, but the observed difference was statistically nonsignificant. CONCLUSION Our data suggest that the treatment benefits of a perindopril-based regimen in patients with vascular disease are independent of statin use.
Collapse
Affiliation(s)
- S P Radhoe
- Department of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands.
| | - E Boersma
- Department of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands
| | | | - W Remme
- STICARES Cardiovascular Research Institute, Rhoon, the Netherlands
| | - R Ferrari
- Department of Cardiology, University of Ferrara, Ferrara, Italy
| | - K Fox
- NHLI, Imperial College and Royal Brompton Hospital, London, UK
| | - S MacMahon
- The George Institute for Global Health, The University of NSW, Sydney, NSW, Australia
| | - J Chalmers
- The George Institute for Global Health, The University of NSW, Sydney, NSW, Australia
| | - M L Simoons
- Department of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands
| | - J J Brugts
- Department of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands
| |
Collapse
|
3
|
Verdonk C, Duffaud AM, Longin A, Bertrand M, Zagnoli F, Trousselard M, Canini F. Posture analysis in predicting fall-related injuries during French Navy Special Forces selection course using machine learning: a proof-of-concept study. BMJ Mil Health 2023:e002542. [PMID: 38124202 DOI: 10.1136/military-2023-002542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 11/20/2023] [Indexed: 12/23/2023]
Abstract
INTRODUCTION Injuries induced by falls represent the main cause of failure in the French Navy Special Forces selection course. In the present study, we made the assumption that probing the posture might contribute to predicting the risk of fall-related injury at the individual level. METHODS Before the start of the selection course, the postural signals of 99 male soldiers were recorded using static posturography while they were instructed to maintain balance with their eyes closed. The event to be predicted was a fall-related injury during the selection course that resulted in the definitive termination of participation. Following a machine learning methodology, we designed an artificial neural network model to predict the risk of fall-related injury from the descriptors of postural signal. RESULTS The neural network model successfully predicted with 69.9% accuracy (95% CI 69.3-70.5) the occurrence of a fall-related injury event during the selection course from the selected descriptors of the posture. The area under the curve value was 0.731 (95% CI 0.725-0.738), the sensitivity was 56.8% (95% CI 55.2-58.4) and the specificity was 77.7% (95% CI 76.8-0.78.6). CONCLUSION If confirmed with a larger sample, these findings suggest that probing the posture using static posturography and machine learning-based analysis might contribute to inform risk assessment of fall-related injury during military training, and could ultimately lead to the development of novel programmes for personalised injury prevention in military population.
Collapse
Affiliation(s)
- Charles Verdonk
- French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
- Laureate Institute for Brain Research, Tulsa, Oklahoma, USA
- VIFASOM, Université Paris Cité, Paris, France
| | - A M Duffaud
- French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
| | - A Longin
- 125th Medical Unit of Lann Bihoué, Lorient, France
| | - M Bertrand
- 6th Special Medical Unit of Orléans-Bricy, Bricy, France
| | - F Zagnoli
- Department of Neurology, Clermont Tonnerre Military Hospital, Brest, France
- French Military Health Academy, Paris, France
| | - M Trousselard
- French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
- French Military Health Academy, Paris, France
| | - F Canini
- French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
- French Military Health Academy, Paris, France
| |
Collapse
|
4
|
Deconinck E, Raimondo M, Borioni A, Grange Y, Rebière H, Mihailova A, Bøyum O, Maurin JK, Pioruńska-Sędłak K, Olsen LS, Acevska J, Brezovska K, Rundlöf T, Portela MJ, Meieranz S, Miquel M, Bertrand M. Clustering of Tadalafil API Samples According to their Manufacturer in the Context of API Falsification Detection. J Pharm Sci 2023; 112:2834-2842. [PMID: 37220827 DOI: 10.1016/j.xphs.2023.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/17/2023] [Accepted: 05/17/2023] [Indexed: 05/25/2023]
Abstract
This paper reports the results of the active pharmaceutical ingredient (API) fingerprint study, organised by the General European Official Medicines Control Laboratory Network (GEON), on tadalafil. A classical market surveillance study, evaluating compliance to the European Pharmacopoeia, was combined with a fingerprint study, the latter to obtain characteristic data for the different manufacturers, allowing the network laboratories to conduct authenticity tests for future samples, as well as to detect substandard and falsified samples. In total, 46 tadalafil API samples from 13 different manufacturers were collected. For all samples fingerprint data was collected through analysis of impurities and residual solvents, mass spectrometric screening, X-ray powder diffraction and proton nuclear magnetic resonance (1H-NMR). Chemometric analysis revealed that all manufacturers could be characterised based on the impurity, residual solvent and 1H-NMR data. Future suspicious samples in the network will therefore be analysed with these techniques in order to attribute the sample to one of the manufacturers. If the sample cannot be attributed, a more profound investigation will be necessary to reveal the origin of the sample. In cases where the suspect sample is claimed to be from one of the manufacturers included in this study, analysis can be limited to the test distinguishing that manufacturer.
Collapse
Affiliation(s)
- E Deconinck
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium.
| | - M Raimondo
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, viale Regina Elena 299, 00161, Rome, Italy
| | - A Borioni
- Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, viale Regina Elena 299, 00161, Rome, Italy
| | - Y Grange
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; French National Agency for Medicines and Health Products Safety (ANSM), Laboratory Controls Division, 635 Rue de la Garenne, F-34740, Vendargues, France
| | - H Rebière
- French National Agency for Medicines and Health Products Safety (ANSM), Laboratory Controls Division, 635 Rue de la Garenne, F-34740, Vendargues, France
| | - A Mihailova
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - O Bøyum
- Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - J K Maurin
- National Medicines Institute, 30/34 Chelmska str., 00-725, Warsaw, Poland
| | - K Pioruńska-Sędłak
- National Medicines Institute, 30/34 Chelmska str., 00-725, Warsaw, Poland
| | - L Stengelshøj Olsen
- Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300, Copenhagen S, Denmark
| | - J Acevska
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North Macedonia
| | - T Rundlöf
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds väg 42, SE-751 03, Uppsala, Sweden
| | - M J Portela
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. Parque de Saúde de Lisboa - Avenida do Brasil, 53, 1749-004, Lisboa, Portugal
| | - S Meieranz
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Landeslabor Berlin-Brandenburg - Institut für Lebensmittel, Arzneimittel, Tierseuchen und Umwelt, Rudower Chaussee 39, 12489, Berlin, Germany
| | - M Miquel
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France
| | - M Bertrand
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France
| |
Collapse
|
5
|
Dumas G, Bertrand M, Lemiale V, Canet E, Barbier F, Kouatchet A, Demoule A, Klouche K, Moreau AS, Argaud L, Wallet F, Raphalen JH, Mokart D, Bruneel F, Pène F, Azoulay E. Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure. Ann Intensive Care 2023; 13:101. [PMID: 37833435 PMCID: PMC10575827 DOI: 10.1186/s13613-023-01196-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Accepted: 09/26/2023] [Indexed: 10/15/2023] Open
Abstract
BACKGROUND Acute respiratory failure (ARF) is the leading cause of ICU admission. Viruses are increasingly recognized as a cause of pneumonia in immunocompromised patients, but epidemiologic data are scarce. We used the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie's database (2003-2017, 72 intensive care units) to describe the spectrum of critically ill immunocompromised patients with virus-detected ARF and to report their outcomes. Then, patients with virus-detected ARF were matched based on clinical characteristics and severity (1:3 ratio) with patients with ARF from other origins. RESULTS Of the 4038 immunocompromised patients in the whole cohort, 370 (9.2%) had a diagnosis of virus-detected ARF and were included in the study. Influenza was the most common virus (59%), followed by respiratory syncytial virus (14%), with significant seasonal variation. An associated bacterial infection was identified in 79 patients (21%) and an invasive pulmonary aspergillosis in 23 patients (6%). The crude in-hospital mortality rate was 37.8%. Factors associated with mortality were: neutropenia (OR = 1.74, 95% confidence interval, CI [1.05-2.89]), poor performance status (OR = 1.84, CI [1.12-3.03]), and the need for invasive mechanical ventilation on the day of admission (OR = 1.97, CI [1.14-3.40]). The type of virus was not associated with mortality. After matching, patients with virus-detected ARF had lower mortality (OR = 0.77, CI [0.60-0.98]) than patients with ARF from other causes. This result was mostly driven by influenza-like viruses, namely, respiratory syncytial virus, parainfluenza virus, and human metapneumovirus (OR = 0.54, CI [0.33-0.88]). CONCLUSIONS In immunocompromised patients with virus-detected ARF, mortality is high, whatever the species, mainly influenced by clinical severity and poor general status. However, compared to non-viral ARF, in-hospital mortality was lower, especially for patients with detected viruses other than influenza.
Collapse
Affiliation(s)
- Guillaume Dumas
- Service de Médecine Intensive-Réanimation, CHU Grenoble-Alpes; Université Grenoble-Alpes, INSERM U1300-HP2, Grenoble, France.
| | - Maxime Bertrand
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
- ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Université de Paris, Paris, France
| | - Virginie Lemiale
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
- ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Université de Paris, Paris, France
| | - Emmanuel Canet
- Nantes Université, CHU Nantes, Médecine Intensive Réanimation, 44000, Nantes, France
| | - François Barbier
- Medical Intensive Care Unit, La Source Hospital, CHR Orleans, Orleans, France
| | - Achille Kouatchet
- Medical Intensive Care Unit, Angers Teaching Hospital, Angers, France
| | - Alexandre Demoule
- Service de Médecine Intensive et Réanimation (Département R3S), Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, and AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Site Pitié-Salpêtrière, 75013, Paris, France
| | - Kada Klouche
- Medical Intensive Care Unit, CHU de Montpellier, Montpellier, France
| | - Anne-Sophie Moreau
- Service de Réanimation Polyvalente, CHRU de Lille - Hôpital Roger Salengro, Lille, France
| | - Laurent Argaud
- Medical Intensive Care Unit, Hospices Civils de Lyon, Hopital Edouard Herriot, Lyon, France
| | - Florent Wallet
- Intensive Care Unit, Lyon Sud Medical Center, Lyon, France
| | | | - Djamel Mokart
- Intensive Care Unit, Institut Paoli Calmettes, Marseille, France
| | - Fabrice Bruneel
- Medical Intensive Care Unit, Andre Mignot Hospital, Versailles, France
| | - Frédéric Pène
- Medical Intensive Care Unit, Cochin Hospital, Hôpitaux Universitaires Paris Centre, AP-HP, Paris, France
- Institut Cochin, INSERM Unité 1016/Centre National de La Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8104/Université de Paris, Paris, France
| | - Elie Azoulay
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital, AP-HP, Paris, France
- ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Université de Paris, Paris, France
| |
Collapse
|
6
|
Semenzato L, Botton J, Drouin J, Barricault B, Bertrand M, Jabagi MJ, Bouillon K, Vu SL, Dray-Spira R, Weill A, Zureik M. Caractéristiques sociodémographiques et médicales associées au risque d’échec d'un schéma vaccinal deux doses contre la COVID-19 en France. Rev Epidemiol Sante Publique 2022. [PMCID: PMC9634433 DOI: 10.1016/j.respe.2022.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Contexte Bien qu'il ait été démontré une efficacité majeure des vaccins contre la COVID-19 pour prévenir les formes sévères de la maladie, il se pose la question d'une meilleure compréhension des facteurs de risque d'échec des vaccins. Objectif Identifier les caractéristiques sociodémographiques et médicales associées au risque d'hospitalisation et/ou de décès hospitalier pour COVID-19 en France après un schéma vaccinal complet. Méthodes L'étude porte sur les données de la base nationale de vaccination COVID-19 VAC-SI couplées au Système national des données de santé (SNDS). L'ensemble des personnes présentant un schéma vaccinal complet en France au 31 juillet 2021 de deux injections vaccinales par mRNA BNT162b2 (Pfizer©), mRNA-1273 (Moderna©), ou ChAdOx1 nCoV-19 (Astrazeneca©), ou d'une unique injection lors d'un diagnostic d'infection préalable au SARS-COV-2, ont été incluses et suivies jusqu'au 31 août 2021. Des modèles de Cox ont été utilisés pour estimer les Hasards Ratios ajustés (HRa) d'hospitalisation et de décès hospitalier pour COVID-19 associés à l'âge, au sexe, à l'indice de défavorisation sociale, aux comorbidités et à la prise de traitements immunosuppresseurs ou de corticoïdes oraux 14 jours après un schéma vaccinal complet. Résultats Un total de 28 031 641 personnes avec un schéma vaccinal complet ont été incluses et suivies pendant en moyenne 80 jours (médiane de 67 jours, IQR 48-105). Au cours de ce suivi, 5 345 (19 pour 100 000) ont été hospitalisées et 996 (4 pour 100 000) sont décédées à l'hôpital pour COVID-19. Dans cette population de sujets vaccinés, les risques respectifs d'hospitalisation et de décès hospitalier pour COVID-19 étaient associés à l'âge (85-89 ans versus 45-54 ans : HRa 4,0 [3,5- 4,7] et HRa 38 [19-75]), au genre masculin (HRa 1,6 [1,5-1,7] et HRa 2,0 [1,7-2,3]) et au niveau de défavorisation sociale (communes les plus défavorisées vs les plus favorisées : HRa 1,3 [1,2-1,4] et HRa 1,5 [1,2-1,9]). Les 47 affections chroniques testées étaient positivement associées à des risques accrus à l'exception de la dyslipidémie. Les associations les plus fortes étaient retrouvées pour la transplantation rénale (HRa 32 [28-37] et 34 [24-47]), la transplantation du poumon (HRa 14 [8,1-23] et 11 [1,5-88]), l'insuffisance rénale en dialyse (HRa 7,0 [5,9-8,2] et HRa 8,6 [6,3-12]), la trisomie 21 (HRa 3,9 [2,1- 7,3] et 45 [16-127]), le retard mental (HRa 3,6 [2,5-5,0] et 3,1 [1,0-10]) et le cancer actif du poumon (HRa 3,5 [2,7-4,4] et 6,5 [4,2-10]). Les risques étaient également augmentés chez les personnes vaccinées traitées par immunosuppresseurs (HRa 3,3 [2,8-3,8] et 2,4 [1,7-3,5]) ou corticoïdes oraux (HRa 2,8 [2,5-3,1] et 4,1 [3,3-5,1]). Moins de 10 % des personnes hospitalisées et 2 % des personnes décédées à l'hôpital ne présentaient aucune comorbidité. Après ajustement, les risques d'hospitalisation et de décès hospitalier augmentaient fortement avec le nombre de comorbidités, atteignant chez les personnes présentant au moins 5 comorbidités des risques multipliés par 10 (HRa 10 [9,0- 11]) et 18 (HRa 18 [11- 27]) respectivement. Conclusion Bien que la vaccination ait très fortement réduit la fréquence des formes sévères de COVID-19, un risque résiduel persistait en particulier dans les populations âgées, immunodéprimées et/ou polypathologiques. Des mesures de prévention complémentaires (gestes barrières) restent nécessaires pour réduire le risque résiduel de formes sévères de COVID-19. Déclaration de liens d'intérêts Les auteurs n'ont pas précisé leurs éventuels liens d'intérêts.
Collapse
Affiliation(s)
- L. Semenzato
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France,Auteur correspondant
| | - J. Botton
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - J. Drouin
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - B. Barricault
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - M. Bertrand
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - M-J. Jabagi
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - K. Bouillon
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - S. Le Vu
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - R. Dray-Spira
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - A. Weill
- EPI-PHARE, épidémiologie des produits de santé (ANSM, Cnam) – EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), France
| | - M. Zureik
- Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), France
| |
Collapse
|
7
|
Vu SL, Bertrand M, Jabagi MJ, Botton J, Drouin J, Baricault B, Weill A, Dray-Spira R, Zureik M. 8Association entre les vaccins COVID-19 à ARN messager et la survenue de myocardite et péricardite chez les personnes de 12 à 50 ans en France. Rev Epidemiol Sante Publique 2022. [PMCID: PMC9634427 DOI: 10.1016/j.respe.2022.09.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
8
|
Landi L, Tiseo M, Heukamp L, Menon R, de Marinis F, Minuti G, Cortinovis D, Delmonte A, Galetta D, Bertrand M, Zacher A, Gridelli C, Jacobs F, Chiari R, Verusio C, Giannarelli D, Crinò L, Cappuzzo F. P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Bertrand M, Bastien C, Boutin I, Vallières A. A psychological view on the effectiveness of psychosocial interventions on positive airway pressure treatment adherence and sleep quality in patients with obstructive sleep apnea. Sleep Med 2022; 91:62-74. [DOI: 10.1016/j.sleep.2021.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 11/18/2021] [Accepted: 11/22/2021] [Indexed: 10/19/2022]
|
10
|
Rebiere H, Grange Y, Deconinck E, Courselle P, Acevska J, Brezovska K, Maurin J, Rundlöf T, Portela MJ, Olsen LS, Offerlé C, Bertrand M. European fingerprint study on omeprazole drug substances using a multi analytical approach and chemometrics as a tool for the discrimination of manufacturing sources. J Pharm Biomed Anal 2022; 208:114444. [PMID: 34773838 DOI: 10.1016/j.jpba.2021.114444] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 10/14/2021] [Accepted: 10/24/2021] [Indexed: 11/29/2022]
Abstract
Like drug products, Active Pharmaceutical Ingredients (APIs) are subject to substandard and falsification issues, which represent a threat to patient health. In order to monitor the quality of drug substances and prevent the use of non-compliant APIs, Official Medicine Control Laboratories work together in a European network developing coordinated strategies and programmes. The API working group proposed a market surveillance study on omeprazole and omeprazole magnesium with the objectives of controlling the pharmaceutical quality of samples, checking compliance with the monographs of the European Pharmacopoeia, and collecting analytical fingerprints that could be further used to differentiate manufacturing sources for future authenticity investigations. The study described in this article reports the analysis carried out by 7 European laboratories on 28 samples from 11 manufacturers with 5 analytical techniques (related substances with HPLC, residual solvents with GC-MS, near infrared spectroscopy, proton nuclear magnetic resonance spectroscopy and X-ray powder diffractometry). The large amount of resulting analytical data were centralized and treated with two chemometric methods: Principal Component Analysis and Hierarchical Clustering Analysis. Data were analyzed separately and in combination (data fusion), allowing us to conclude that NMR and XRPD were suitable to differentiate samples originating from 9 out of 11 manufacturers. Analytical fingerprints associated with chemometrics were demonstrated to be a valuable methodology to discriminate manufacturers of omeprazole and omeprazole magnesium APIs and detect future substandard and falsified APIs.
Collapse
Affiliation(s)
- H Rebiere
- French National Agency for Medicines and Health Products Safety, ANSM, Laboratory Controls Division, 635 Rue de la Garenne, 34740 Vendargues, France.
| | - Y Grange
- French National Agency for Medicines and Health Products Safety, ANSM, Laboratory Controls Division, 635 Rue de la Garenne, 34740 Vendargues, France; Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France
| | - E Deconinck
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Sciensano, Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, J. Wytsmanstraat 14, B-1050 Brussels, Belgium
| | - P Courselle
- Sciensano, Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, J. Wytsmanstraat 14, B-1050 Brussels, Belgium
| | - J Acevska
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000 Skopje, Republic of North Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000 Skopje, Republic of North Macedonia
| | - J Maurin
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; National Medicines Institute, Falsified Medicines and Medical Devices Department, 30/34 Chelmska str., 00-725 Warsaw, Poland
| | - T Rundlöf
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds väg 42, SE-751 03 Uppsala, Sweden
| | - M J Portela
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Infarmed - National Authority of Medicines and Health Products, I.P., Parque de Saúde de Lisboa - Avenida do Brasil 53, 1749-004 Lisboa, Portugal
| | - L S Olsen
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France; Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300 Copenhagen S, Denmark
| | - C Offerlé
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France
| | - M Bertrand
- Active Pharmaceutical Ingredient Working Group, GEON, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France
| |
Collapse
|
11
|
Deconinck E, Courselle P, Raimondo M, Grange Y, Rebière H, Mihailova A, Bøyum O, Maurin JK, Pioruńska-Sędłak K, Olsen LS, Acevska J, Brezovska K, Rundlöf T, Portela MJ, Bertrand M. GEONs API fingerprint project: Selection of analytical techniques for clustering of sildenafil citrate API samples. Talanta 2021; 239:123123. [PMID: 34942486 DOI: 10.1016/j.talanta.2021.123123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 11/25/2021] [Accepted: 12/01/2021] [Indexed: 11/19/2022]
Abstract
Through its Active Pharmaceutical Ingredient Working Group (API-WG) the General European Official Medicines Control Laboratory (OMCL) Network (GEON), co-ordinated by the European Directorate for the Quality of Medicines & HealthCare (EDQM), regularly organises market surveillance studies for specific APIs for conformity to their monograph in the European Pharmacopoeia. During the past years some studies were combined with a fingerprint study of the APIs. The idea is to obtain a fingerprint for each manufacturer of the API under investigation, allowing the OMCL network to identify future samples as well as to detect substandard and falsified APIs. This paper reports the results of the latest fingerprint study, organised on sildenafil citrate API samples. Seventy-nine samples from 14 different manufacturers were collected throughout the Network. Fingerprint data was collected through Mid-Infrared spectroscopy, Raman spectroscopy, liquid chromatography for related substances, gas chromatography for residual solvents, X-ray diffraction and Nuclear Magnetic Resonance (NMR) spectroscopy. Chemometrics applied to the collected data showed that all manufacturers could be discriminated based on the data of only three of these tests, i.e. gas chromatography for residual solvents, X-ray diffraction and proton NMR. Suspicious API samples for sildenafil citrate will therefore be analysed in the future with the selected techniques in order to link the sample to a manufacturer or demonstrate the absence of such link. If the sample cannot be attributed to one of the manufacturers, further analysis and research on provenance and identity will be required. Of course, if the suspected sample claims to originate from one of the manufacturers included in the study, analysis can be limited to the test distinguishing this manufacturer.
Collapse
Affiliation(s)
- E Deconinck
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium.
| | - P Courselle
- Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium
| | - M Raimondo
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, Viale Regina Elena 299, 00161, Rome, Italy
| | - Y Grange
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; French National Agency for Medicines and Health Products Safety, Laboratory Controls Division, 635 Rue de la Garenne, 34740, Vendargues, France
| | - H Rebière
- French National Agency for Medicines and Health Products Safety, Laboratory Controls Division, 635 Rue de la Garenne, 34740, Vendargues, France
| | - A Mihailova
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - O Bøyum
- Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - J K Maurin
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; National Medicines Institute, 30/34 Chelmska Str., 00-725, Warsaw, Poland
| | - K Pioruńska-Sędłak
- National Medicines Institute, 30/34 Chelmska Str., 00-725, Warsaw, Poland
| | - L Stengelshøj Olsen
- Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300, Copenhagen S, Denmark
| | - J Acevska
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Center for Drug Quality Control, Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, University Ss.Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North-Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, University Ss.Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North-Macedonia
| | - T Rundlöf
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds Väg 42, SE-751 03, Uppsala, Sweden
| | - M J Portela
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France; INFARMED, Autoridade Nacional Do Medicamento e Produtos de Saúde, I.P. Parque de Saúde de Lisboa, Avenida Do Brasil, 531749-004, Lisboa, Portugal
| | - M Bertrand
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 Allée Kastner, CS 30026, F-67081, Strasbourg, France
| |
Collapse
|
12
|
Saikali E, Bois G, Rodio M, Bieder U, Burlot A, Bertrand M. Validation of the hydrodynamics in a turbulent un-baffled vortex reactor at two different stirring Reynolds numbers. Nuclear Engineering and Design 2021. [DOI: 10.1016/j.nucengdes.2021.111450] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Allonneau A, Villeneuve JP, Sempere H, Couderc A, Nicaise A, Soula M, Kerrien C, Minaberry S, Bertrand M, Mourougou M, Coste S. [The contribution of teleconsultation and isolation of symptomatic cases in control of the COVID-19 outbreak a military base]. Rev Epidemiol Sante Publique 2021; 69:167-171. [PMID: 34119362 PMCID: PMC8162725 DOI: 10.1016/j.respe.2021.05.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 04/25/2021] [Accepted: 05/12/2021] [Indexed: 12/01/2022] Open
Abstract
Position du problème La première vague de la COVID-19 a déferlé sur la France au cours du premier trimestre 2020 entraînant une saturation du réseau de soins. Nous avons voulu étudier, au sein d’une antenne médicale militaire française soutenant un des plus grands effectifs des armées, l’impact de la téléconsultation ainsi que de l’isolement systématique de tous les cas possibles, probables et confirmés de COVID-19. Méthodes Il s’agit d’une étude rétrospective réalisée du 9 mars au 31 mai 2020 à partir de notre registre d’activité. Les variables recueillies étaient notamment le type d’épisode, le statut professionnel, la classification du cas et la date de début des symptômes. Nous avons mis en parallèle notre activité à celle de SOS Médecins et des services d’urgence d’Île-de-France. Résultats et discussion Au cours de cette période, 1719 épisodes de soins (téléconsultations ou consultations physiques) ont été enregistrés dont 91 % (n = 1561) en lien avec la COVID-19. Nous avons identifié 598 cas “suspects” (possibles et probables) et confirmés. Les téléconsultations “isolées” (non suivies d’une consultation médicale en présentiel, d’un prélèvement ou ayant nécessité l’envoi de prompt-secours) ont représenté 86 % des épisodes de soins (n = 1482). La comparaison de notre activité et du nombre de nouveaux cas aux bases de données de SOS Médecins et des services d’urgences d’Île-de-France laisse supposer que notre stratégie d’isolement a été rapidement efficace. Conclusion L’apport de la téléconsultation a été majeur et sécurisant. La téléconsultation permet d’absorber un volume de patients important, est facile à mettre en œuvre et se caractérise par l’absence de risque nosocomial. L’isolement des patients contaminés doit constituer une priorité en période épidémique. Cette attitude doit s’étendre, lorsque l’on veut maitriser rapidement une épidémie, à l’ensemble des patients symptomatiques.
Collapse
Affiliation(s)
| | | | - H Sempere
- Centre médical des armées de Paris, France
| | - A Couderc
- Centre médical des armées de Paris, France
| | - A Nicaise
- Centre médical des armées de Paris, France
| | - M Soula
- Centre médical des armées de Paris, France
| | - C Kerrien
- Centre médical des armées de Paris, France
| | | | - M Bertrand
- Centre médical des armées de Paris, France
| | | | - S Coste
- Centre médical des armées de Paris, France
| |
Collapse
|
14
|
Pottier E, Boulanouar L, Bertrand M, Estrade A, Croiset A, Martineau C, Plantec JY, Escourou B, Ritz P. A MOOC About Bariatric Surgery Improves Knowledge and Promotes Patients' Soft Skills. Obes Surg 2021; 30:1600-1604. [PMID: 31471766 DOI: 10.1007/s11695-019-04143-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The ASMBS recommends that patients should be provided with educational materials to improve informed consent about bariatric surgery. Massive online open courses (MOOCs) are learning sources which are free, online, and available to people in remote situations. A French language MOOC regarding preparation for obesity surgery targets patients, as well as HCP, and people curious about this treatment. The patients' knowledge and skills after completion of the 5-week learning sessions (evaluated with semi-direct interviews) improved. Soft skills such as feeling empowered to ask questions to their HCP and explaining their plan to their relatives improved. This study suggests that MOOC can be a resource to improve knowledge and soft skills in patients for a better consent to surgery and follow-up.
Collapse
Affiliation(s)
- E Pottier
- Nutrition Department, CIO and CHU, Toulouse, France
| | - L Boulanouar
- Nutrition Department, CIO and CHU, Toulouse, France
| | - M Bertrand
- Nutrition Department, CIO and CHU, Toulouse, France
| | - A Estrade
- Nutrition Department, CIO and CHU, Toulouse, France
| | - A Croiset
- Nutrition Department, CIO and CHU, Toulouse, France
| | - C Martineau
- Dietetics Department, CIO and CHU, Toulouse, France
| | | | - B Escourou
- Département Universitaire de Médecine Générale, University Paul Sabatier, Toulouse, France
| | - P Ritz
- Nutrition Department, CIO and CHU, Toulouse, France.
- Inserm U1027, University Paul Sabatier, Toulouse, France.
| |
Collapse
|
15
|
Graillat L, Ritz P, Estrade A, Bertrand M, Montastier E, Tuyeras G, Lijeron J. Évaluation d’une semaine à thème d’éducation thérapeutique destinée à des patients ayant repris du poids après une chirurgie bariatrique au CHU de Toulouse. NUTR CLIN METAB 2021. [DOI: 10.1016/j.nupar.2021.01.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Saikali E, Bois G, Rodio M, Bieder U, Bertrand M, Leterrier N, Dolias Y. Influence of the hydrodynamics and the reaction-rate formulation in modeling infinitely fast irreversible reactions in a turbulent un-baffled chemical reactor. CHEM ENG COMMUN 2020. [DOI: 10.1080/00986445.2020.1864627] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- E. Saikali
- Université Paris-Saclay, CEA, Service de Thermo-hydraulique et de Mécanique des Fluides, 91191, Gif-sur-Yvette, France
| | - G. Bois
- Université Paris-Saclay, CEA, Service de Thermo-hydraulique et de Mécanique des Fluides, 91191, Gif-sur-Yvette, France
| | - M.G. Rodio
- Université Paris-Saclay, CEA, Service de Thermo-hydraulique et de Mécanique des Fluides, 91191, Gif-sur-Yvette, France
| | - U. Bieder
- Université Paris-Saclay, CEA, Service de Thermo-hydraulique et de Mécanique des Fluides, 91191, Gif-sur-Yvette, France
| | - M. Bertrand
- CEA, Département de Recherche sur les Procédés pour la Mine et le Recyclage du Combustible, 30207, Bagnols-sur-Céze, France
| | - N. Leterrier
- Université Paris-Saclay, CEA, Service de Thermo-hydraulique et de Mécanique des Fluides, 91191, Gif-sur-Yvette, France
| | - Y. Dolias
- CEA, Direction des Partenariats Industriels, 38000, Grenoble, France
| |
Collapse
|
17
|
Manceau G, Sabbagh C, Mege D, Lakkis Z, Bege T, Tuech JJ, Benoist S, Lefèvre JH, Karoui M, Bridoux V, Venara A, Beyer‐Berjot L, Codjia T, Dazza M, Gagnat G, Hamel S, Mallet L, Martre P, Philouze G, Roussel E, Tortajada P, Dumaine AS, Heyd B, Paquette B, Brunetti F, Esposito F, Lizzi V, Michot N, Denost Q, Rullier E, Tresallet C, Tetard O, Rivier P, Fayssal E, Collard M, Moszkowicz D, Lupinacci R, Peschaud F, Etienne JC, Loge L, Bege T, Corte H, D’Annunzio E, Humeau M, Issard J, Munoz N, Abba J, Jafar Y, Lacaze L, Sage PY, Susoko L, Trilling B, Arvieux C, Mauvais F, Ulloa‐Severino B, Pitel S, Vauchaussade de Chaumont A, Badic B, Blanc B, Bert M, Rat P, Ortega‐Deballon P, Chau A, Dejeante C, Piessen G, Grégoire E, Alfarai A, Cabau M, David A, Kadoche D, Dufour F, Goin G, Goudard Y, Pauleau G, Sockeel P, Villeon B, Pautrat K, Eveno C, Abdalla S, Couchard AC, Balbo G, Mabrut JY, Bellinger J, Bertrand M, Aumont A, Duchalais E, Messière AS, Tranchart A, Cazauran JB, Pichot‐Delahaye V, Dubuisson V, Maggiori L, Panis Y, Djawad‐Boumediene B, Fuks D, Kahn X, Huart E, Catheline JM, Lailler G, Baraket O, Baque P, Diaz de Cerio JM, Mariol P, Maes B, Fernoux P, Guillem P, Chatelain E, de Saint Roman C, Fixot K, Voron T, Parc Y. Colon sparing resection versus extended colectomy for left-sided obstructing colon cancer with caecal ischaemia or perforation: a nationwide study from the French Surgical Association. Colorectal Dis 2020; 22:1304-1313. [PMID: 32368856 DOI: 10.1111/codi.15111] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 04/02/2020] [Indexed: 02/08/2023]
Abstract
AIM It is not known whether patients with obstructive left colon cancer (OLCC) with caecal ischaemia or diastatic perforation (defined as a blowout of the caecal wall related to colonic overdistension) should undergo a (sub)total colectomy (STC) or an ileo-caecal resection with double-barrelled ileo-colostomy. We aimed to compare the results of these two strategies. METHOD From 2000 to 2015, 1220 patients with OLCC underwent surgery by clinicians who were members of the French Surgical Association. Of these cases, 201 (16%) were found to have caecal ischaemia or diastatic perforation intra-operatively: 174 patients (87%) underwent a STC (extended colectomy group) and 27 (13%) an ileo-caecal resection with double-end stoma (colon-sparing group). Outcomes were compared retrospectively. RESULTS In the extended colectomy group, 95 patients (55%) had primary anastomosis and 79 (45%) had a STC with an end ileostomy. In the colon-sparing group, 10 patients (37%) had simultaneous resection of their primary tumour with segmental colectomy and an anastomosis which was protected by a double-barrelled ileo-colostomy. The demographic data for the two groups were comparable. Median operative time was longer in the STC group (P = 0.0044). There was a decrease in postoperative mortality (7% vs 12%, P = 0.75) and overall morbidity (56% vs 67%, P = 0.37) including surgical (30% vs 40%, P = 0.29) and severe complications (17% vs 27%, P = 0.29) in the colon-sparing group, although these differences did not reach statistical significance. Cumulative morbidity included all surgical stages and the rate of permanent stoma was 66% and 37%, respectively, with no significant difference between the two groups. Overall survival and disease-free survival were similar between the two groups. CONCLUSION The colon-sparing strategy may represent a valid and safe alternative to STC in OLCC patients with caecal ischaemia or diastatic perforation.
Collapse
Affiliation(s)
- G Manceau
- Department of Digestive Surgery, Assistance Publique-Hôpitaux de Paris, Pitié Salpêtrière University Hospital, Sorbonne Université, Paris, France
| | - C Sabbagh
- Department of Digestive Surgery, Amiens University Hospital, Amiens, France
| | - D Mege
- Department of Digestive Surgery, Assistance Publique-Hôpitaux de Marseille, Timone University Hospital, Marseille, France
| | - Z Lakkis
- Department of Digestive Surgery, Besançon University Hospital, Besançon, France
| | - T Bege
- Department of Digestive Surgery, Assistance Publique Hôpitaux de Marseille, North University Hospital, Marseille, France
| | - J J Tuech
- Department of Digestive Surgery, Charles Nicolle University Hospital, Rouen, France
| | - S Benoist
- Department of Digestive Surgery, Assistance Publique-Hôpitaux de Paris, Bicêtre University Hospital, Université Paris-Sud, Le Kremlin Bicêtre, France
| | - J H Lefèvre
- Department of Digestive Surgery, Assistance Publique-Hôpitaux de Paris, Saint-Antoine University Hospital, Sorbonne Université, Paris, France
| | - M Karoui
- Department of Digestive Surgery, Assistance Publique-Hôpitaux de Paris, Pitié Salpêtrière University Hospital, Sorbonne Université, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Saikali E, Rodio M, Bois G, Bieder U, Leterrier N, Bertrand M, Dolias Y. Validation of the hydrodynamics in a turbulent un-baffled stirred tank: A necessity for vortex-reactor precipitation studies. Chem Eng Sci 2020. [DOI: 10.1016/j.ces.2019.115426] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Bertrand M, Devilez A, Hugonin JP, Lalanne P, Vynck K. Global polarizability matrix method for efficient modeling of light scattering by dense ensembles of non-spherical particles in stratified media. J Opt Soc Am A Opt Image Sci Vis 2020; 37:70-83. [PMID: 32118883 DOI: 10.1364/josaa.37.000070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 11/12/2019] [Indexed: 06/10/2023]
Abstract
We introduce a numerical method that enables efficient modeling of light scattering by large, disordered ensembles of non-spherical particles incorporated in stratified media, including when the particles are in close vicinity to each other, to planar interfaces, and/or to localized light sources. The method consists of finding a small set of fictitious polarizable elements-or numerical dipoles-that quantitatively reproduces the field scattered by an individual particle for any excitation and at an arbitrary distance from the particle surface. The set of numerical dipoles is described by a global polarizability matrix that is determined numerically by solving an inverse problem relying on fullwave simulations. The latter are classical and may be performed with any Maxwell's equations solver. Spatial non-locality is an important feature of the numerical dipoles set, providing additional degrees of freedom compared to classical coupled dipoles to reconstruct complex scattered fields. Once the polarizability matrix describing scattering by an individual particle is determined, the multiple scattering problem by ensembles of such particles in stratified media can be solved using a Green tensor formalism and only a few numerical dipoles, thereby with a low physical memory usage, even for dense systems in close vicinity to interfaces. The performance of the method is studied with the example of large high-aspect-ratio high-index dielectric cylinders. The method is easy to implement and may offer new possibilities for the study of complex nanostructured surfaces, which are becoming widespread in emerging photonic technologies.
Collapse
|
20
|
Landi L, Tiseo M, Heukamp L, Menon R, Spitaleri G, Cortinovis D, Delmonte A, Galetta D, D’Arcangelo M, D’Incà F, Bertrand M, Jóri B, Zacher A, Gridelli C, Novello S, Chiari R, Verusio C, Crinò L, Cappuzzo F. Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Durain J, Bourgeois D, Bertrand M, Meyer D. Comprehensive Studies on Third Phase Formation: Application to U(VI)/Th(IV) Mixtures Extracted by TBP in N-dodecane. Solvent Extraction and Ion Exchange 2019. [DOI: 10.1080/07366299.2019.1656853] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- J. Durain
- ICSM, CEA, CNRS, ENSCM, University of Montpellier, Marcoule, France
| | - D. Bourgeois
- ICSM, CEA, CNRS, ENSCM, University of Montpellier, Marcoule, France
| | - M. Bertrand
- Département de recherche sur les procédés pour la mine et le recyclage du combustible (DMRC), Commissariat à l’Energie Atomique et aux Energies alternatives de Marcoule (CEA), Bagnols-sur-Cèze Cedex, France
| | - D. Meyer
- ICSM, CEA, CNRS, ENSCM, University of Montpellier, Marcoule, France
| |
Collapse
|
22
|
Manceau G, Mege D, Bridoux V, Lakkis Z, Venara A, Voron T, De Angelis N, Ouaissi M, Sielezneff I, Karoui M, Dazza M, Gagnat G, Hamel S, Mallet L, Martre P, Philouze G, Roussel E, Tortajada P, Dumaine AS, Heyd B, Paquette B, Brunetti F, Esposito F, Lizzi V, Michot N, Denost Q, Tresallet C, Tetard O, Regimbeau JM, Sabbagh C, Rivier P, Fayssal E, Collard M, Moszkowicz D, Peschaud F, Etienne JC, loge L, Beyer L, Bege T, Corte H, D'Annunzio E, Humeau M, Issard J, Munoz N, Abba J, Jafar Y, Lacaze L, Sage PY, Susoko L, Trilling B, Arvieux C, Mauvais F, Ulloa‐Severino B, Lefevre JH, Pitel S, Vauchaussade de Chaumont A, Badic B, Blanc B, Bert M, Rat P, Ortega‐Deballon P, Chau A, Dejeante C, Piessen G, Grégoire E, Alfarai A, Cabau M, David A, Kadoche D, Dufour F, Goin G, Goudard Y, Pauleau G, Sockeel P, De la Villeon B, Pautrat K, Eveno C, Brouquet A, Couchard AC, Balbo G, Mabrut JY, Bellinger J, Bertrand M, Aumont A, Duchalais E, Messière AS, Tranchart A, Cazauran JB, Pichot‐Delahaye V, Dubuisson V, Maggiori L, Djawad‐Boumediene B, Fuks D, Kahn X, Huart E, Catheline JM, Lailler G, Baraket O, Baque P, Diaz de Cerio JM, Mariol P, Maes B, Fernoux P, Guillem P, Chatelain E, de Saint Roman C, Fixot K. Thirty-day mortality after emergency surgery for obstructing colon cancer: survey and dedicated score from the French Surgical Association. Colorectal Dis 2019; 21:782-790. [PMID: 30884089 DOI: 10.1111/codi.14614] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2018] [Accepted: 02/27/2019] [Indexed: 02/08/2023]
Abstract
AIM The aim was to define risk factors for postoperative mortality in patients undergoing emergency surgery for obstructing colon cancer (OCC) and to propose a dedicated score. METHOD From 2000 to 2015, 2325 patients were treated for OCC in French surgical centres by members of the French National Surgical Association. A multivariate analysis was performed for variables with P value ≤ 0.20 in the univariate analysis for 30-day mortality. Predictive performance was assessed by the area under the receiver operating characteristic curve. RESULTS A total of 1983 patients were included. Thirty-day postoperative mortality was 7%. Multivariate analysis found five significant independent risk factors: age ≥ 75 (P = 0.013), American Society of Anesthesiologists (ASA) score ≥ III (P = 0.027), pulmonary comorbidity (P = 0.0002), right-sided cancer (P = 0.047) and haemodynamic failure (P < 0.0001). The odds ratio for risk of postoperative death was 3.42 with one factor, 5.80 with two factors, 15.73 with three factors, 29.23 with four factors and 77.25 with five factors. The discriminating capacity in predicting 30-day postoperative mortality was 0.80. CONCLUSION Thirty-day postoperative mortality after emergency surgery for OCC is correlated with age, ASA score, pulmonary comorbidity, site of tumour and haemodynamic failure, with a specific score ranging from 0 to 5.
Collapse
Affiliation(s)
- G Manceau
- Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Sorbonne Université, Paris, France
| | - D Mege
- Department of Digestive Surgery, Timone University Hospital, Marseille, France
| | - V Bridoux
- Department of Digestive Surgery, Charles Nicolle University Hospital, Rouen, France
| | - Z Lakkis
- Department of Digestive Surgery, Besançon University Hospital, Besançon, France
| | - A Venara
- Department of Digestive Surgery, Angers University Hospital, Angers, France
| | - T Voron
- Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Saint Antoine Hospital, Sorbonne Université, Paris, France
| | - N De Angelis
- Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Henri Mondor Hospital, Université Paris-Est (UEP), Créteil, France
| | - M Ouaissi
- Department of Digestive Surgery, Tours University Hospital, Tours, France
| | - I Sielezneff
- Department of Digestive Surgery, Timone University Hospital, Marseille, France
| | - M Karoui
- Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière Hospital, Sorbonne Université, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Gohier H, Cintas P, Montastier E, Bertrand M, Tuyeras G, Chalret du Rieu M, Estrade A, Ritz P. A Case Report of Myotonic Disease and Gastric Bypass and a Literature Review. Obes Surg 2019; 29:2355-2356. [PMID: 31054108 DOI: 10.1007/s11695-019-03913-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We report the case of a woman with myotonic dystrophy type 1, followed for 8 years after a Roux-en-Y gastric bypass. Weigh loss was substantial (53% of initial body weight) with functional improvement in spite of the natural course of the pathology. Five other cases have been published and have reported a relatively positive benefit/risk ratio. Precautions are to be taken at the time of anesthesia and follow-up in order to detect possible degradation of muscle function.
Collapse
Affiliation(s)
- H Gohier
- Nutrition Department, CIO and CHU, Toulouse, France
| | - P Cintas
- Neurology Department, CHU, Toulouse, France
| | - E Montastier
- Nutrition Department, CIO and CHU, Toulouse, France
| | - M Bertrand
- Nutrition Department, CIO and CHU, Toulouse, France
| | - G Tuyeras
- Surgery Department, CIO and CHU, Toulouse, France
| | | | - A Estrade
- Nutrition Department, CIO and CHU, Toulouse, France
| | - P Ritz
- Nutrition Department, CIO and CHU, Toulouse, France. .,Inserm U1027, University Paul Sabatier, Toulouse, France.
| |
Collapse
|
24
|
Hengsbach A, Lakis S, Heitz F, Talwar A, Sehouli J, Bommert M, Bertrand M, Ataseven B, Müller JN, Schneider S, Mariotti E, Prader S, Menon R, Leenders F, Heukamp LC, Braicu I, Glöckner C, du Bois A, Heuckmann JM. Liquid biopsy zur objektiven Beurteilung des post-operativen Tumorrestes bei Patientinnen mit fortgeschrittenem high-grade serösem Ovarialkarzinom. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Hengsbach
- Kliniken Essen-Mitte (KEM), Gynäkologische Onkologie, Essen, Deutschland
| | - S Lakis
- NEO New Oncology, Köln, Deutschland
| | - F Heitz
- Kliniken Essen-Mitte (KEM), Essen, Deutschland
| | - A Talwar
- NEO New Oncology, Köln, Deutschland
| | - J Sehouli
- Charité – Universitätsmedizin Berlin, Berlin, Deutschland
| | - M Bommert
- Kliniken Essen Mitte, Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | | | - B Ataseven
- Kliniken Essen Mitte, Essen, Deutschland
| | | | - S Schneider
- Kliniken Essen Mitte, Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | | | - S Prader
- Kliniken Essen Mitte, Essen, Deutschland
| | - R Menon
- NEO New Oncology, Köln, Deutschland
| | | | | | - I Braicu
- Charité – Universitätsmedizin Berlin, Berlin, Deutschland
| | | | - A du Bois
- Kliniken Essen Mitte, Essen, Deutschland
| | | |
Collapse
|
25
|
Bonard P, Tremblay G, LeBlanc AR, Bertrand M, Roberge FA. A New Method for the Precise and Complete Correction of Distortion on Cineangiographic Image: Its Effect on Left Ventricular Measurements. ACTA ACUST UNITED AC 2018. [DOI: 10.1002/ccd.1978.4.2.111] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
26
|
Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1656122] [Citation(s) in RCA: 164] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryFactor VIII or factor IX replacement is frequently impossible in inhibitor-developing hemophiliacs, because of the level of the inhibitor titer. Activated prothrombin complex concentrates are one of the available options to treat the bleeding episodes in such patients. However, the efficacy of these products and the associated thrombogenic risk, particularly in prolonged administration such as employed during surgeries, are important concerns for hemophilia care providers. We performed a multicenter retrospective study to evaluate the use of FEIBA (Factor Eight Bypassing Activity) in France, and data is presented on 433 bleeding episodes, including surgical procedures, concerning 60 patients from 15 hemophilia centers.The efficacy was judged as good or excellent in 352 episodes (81.3%), poor in 73 episodes (16.9%) and non-existent in 8 episodes (1.8%). Minor and major surgical procedures were successfully performed using FEIBA as a second-line therapy after human or porcine factor VIII, and in some occasions FEIBA was utilized as the only substitution product. The tolerance was assessed as good in 428 episodes (98.8%), but in 5 cases adverse effects were reported. Only 3 patients out of 52 regularly evaluated (5.8%) were HIV-seropositive, and for two of them the seroconversion occurred prior to the first use of FEIBA. In contrast, 80.4% of the patients were HCV-seropositive. An anamnestic response after the administration of FEIBA was noted in 31.5% of cases. This study points out the main features of the use of FEIBA in France, and particularly the low HIV seroprevalence in the patients treated. The good efficacy and the excellent tolerance still confer to this product a place to consider in the therapeutic options for the treatment of inhibitor-developing hemophiliacs or in acquired hemophilia.
Collapse
Affiliation(s)
- C Negrier
- The Hemophilia Comprehensive Care Centers, Hôpita1 Edouard Herriot, Lyon, France
| | - J Goudemand
- The Hemophilia Comprehensive Care Centers, Hôpital Claude Huriez, Lille, France
| | - Y Sultan
- The Hemophilia Comprehensive Care Centers, Hôpital Cochin, Paris, France
| | - M Bertrand
- The Hemophilia Comprehensive Care Centers, Hôpital Saint Jacques, Besançon, Bordeaux, France
| | - C Rothschild
- The Hemophilia Comprehensive Care Centers, Hôpital Necker, Paris, France
| | - P Lauroua
- The Hemophilia Comprehensive Care Centers, Centre de Transfusion Sanguine, Bordeaux, France
| | | |
Collapse
|
27
|
Brugts JJ, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Boersma E. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Cardiovasc Drugs Ther 2018; 31:391-400. [PMID: 28856537 PMCID: PMC5607906 DOI: 10.1007/s10557-017-6747-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION In everyday practice, angiotensin converting enzyme inhibitors and beta-blockers are cornerstone treatments in patients with (cardio-)vascular disease. Clear data that evaluate the effects of the combination of these agents on morbidity and mortality are lacking. METHODS In this retrospective pooled analysis of three large perindopril outcome trials (ADVANCE, EUROPA, PROGRESS), clinical outcomes were evaluated in 29,463 patients with vascular disease. Multivariate Cox regression analyses were performed in patients randomized to a perindopril-based regimen or placebo (treatment effect), and data were stratified according to background beta-blocker treatment. The primary endpoint was a composite of cardiovascular mortality, non-fatal myocardial infarction, and stroke. RESULTS The cumulative incidence of the primary endpoint over mean follow-up of 4.0 years (Sd 1.0) was significantly lower in the beta-blocker/perindopril group (9.6%; 545/5700 patients) as compared to beta-blocker/placebo (11.8%; 676/5718 patients) (p < 0.01). Adding perindopril to existing beta-blocker treatment reduced the relative risk of the primary endpoint by 20% (hazard ratio (HR) 0.80; 95% confidence interval (CI) 0.71-0.90), non-fatal myocardial infarction by 23% (HR 0.77; 95% CI 0.65-0.91), and all-cause mortality by 22% (HR 0.78; 95% CI 0.68-0.88) as compared to placebo. Significant treatment benefit was not observed for stroke (HR 0.93; 95% CI 0.75-1.15). Significance was maintained for the primary endpoint and cardiovascular endpoints when data were further stratified by baseline hypertension. However, the mortality benefit was only observed in patients with hypertension with background beta-blocker use. CONCLUSIONS These data suggest that the beneficial cardioprotective effects of perindopril treatment are additive to the background beta-blockers use.
Collapse
Affiliation(s)
- J J Brugts
- Department of Cardiology, Erasmus University Medical Center, Thoraxcenter, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
| | | | - W Remme
- STICARES Cardiovascular Research Institute, Rhoon, The Netherlands
| | - R Ferrari
- Centro Cardiologico Universitario University of Ferrara, Italy and Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Ravenna, Italy
| | - K Fox
- NHLI, Imperial College and ICMS, Royal Brompton Hospital, London, UK
| | - S MacMahon
- The George Institute for Global Health, The Royal Prince Alfred Hospital and the University of Sydney, Sydney, New South Wales, Australia
| | - J Chalmers
- The George Institute for Global Health, The Royal Prince Alfred Hospital and the University of Sydney, Sydney, New South Wales, Australia
| | - M L Simoons
- Department of Cardiology, Erasmus University Medical Center, Thoraxcenter, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
| | - E Boersma
- Department of Cardiology, Erasmus University Medical Center, Thoraxcenter, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
| |
Collapse
|
28
|
Fovet T, Bertrand M, Horn M, Si Mohammed W, Dandelot D, Dalle MC, Thomas P, Amad A. [Involuntary psychiatric care for inmates in France: Only for "dangerous" patients?]. Encephale 2017; 44:568-570. [PMID: 29191374 DOI: 10.1016/j.encep.2017.09.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Revised: 08/23/2017] [Accepted: 09/06/2017] [Indexed: 11/25/2022]
Abstract
The unités hospitalières spécialement aménagées (UHSA) are full-time inpatient psychiatric units for inmates in France. Their creation has been associated with several advances in access to psychiatric care for inmates in recent years. However, there is still only one means of involuntary hospitalization for prisoners in France: care by decision of a representative of the state (les soins sur décision d'un représentant de l'état [SDRE]). Interestingly, for SDRE to be recognized as legal by the French judge, the patient must be "a danger to himself or to the others". Thus, there is a major difference with involuntary hospitalization outside the prison, and there are specific criteria for involuntary psychiatric hospitalization for inmates in France. This situation questions the general framework of involuntary psychiatric care and is very inconsistent with French law. Indeed, the goal of the loi no 94-43 du 18 janvier 1994 relating to public health and social protection is to ensure equivalent care for all patients, incarcerated or not.
Collapse
Affiliation(s)
- T Fovet
- Pôle de psychiatrie, CHU de Lille, 59000 Lille, France; CNRS UMR 9193, laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), université de Lille, 59000 Lille, France.
| | - M Bertrand
- Pôle de psychiatrie, CHU de Lille, 59000 Lille, France
| | - M Horn
- Pôle de psychiatrie, CHU de Lille, 59000 Lille, France; CNRS UMR 9193, laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), université de Lille, 59000 Lille, France
| | - W Si Mohammed
- UHSA de Cadillac, pole psychiatrie médico-légale, centre hospitalier de Cadillac s/Garonne, 33410 Cadillac, France
| | - D Dandelot
- UHSA de Cadillac, pole psychiatrie médico-légale, centre hospitalier de Cadillac s/Garonne, 33410 Cadillac, France
| | - M-C Dalle
- Pôle de psychiatrie, CHU de Lille, 59000 Lille, France
| | - P Thomas
- Pôle de psychiatrie, CHU de Lille, 59000 Lille, France; CNRS UMR 9193, laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), université de Lille, 59000 Lille, France
| | - A Amad
- Pôle de psychiatrie, CHU de Lille, 59000 Lille, France; CNRS UMR 9193, laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), université de Lille, 59000 Lille, France
| |
Collapse
|
29
|
Bertrand M, Clanet M, Didier A, Lepage B, Ghisolfi A, Robert C, Podevin M, Frazao S, Ritz P. Comparaison de deux stratégies de dépistage des troubles nutritionnels en MCO. NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2017.06.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Lakis S, Mueller J, Bertrand M, Heuckmann J, Menon R, Netchaeva M, Roeper J, Heukamp L, Griesinger F. Detection of activating EGFR and KRAS mutations in a single liquid biopsy from a patient with adenocarcinoma of the lung using hybrid capture based sequencing. Pneumologie 2017. [DOI: 10.1055/s-0037-1598273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | | | | | | | | | | | - J Roeper
- Pius-Hospital, Universität Oldenburg
| | | | - F Griesinger
- Department of Hematology and Oncology, Pius-Hospital Oldenburg, University Hospital
| |
Collapse
|
31
|
Marechal P, Dube M, Bertrand M, Grosz S, Meynier F, Barranger C, Joannes M. CMV Run control r-gene® (ARGENE® range, bioMérieux): A tool to ensure the reliability of human cytomegalovirus nucleic acid amplification technique results. J Clin Virol 2016. [DOI: 10.1016/j.jcv.2016.08.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Bertrand M, Vaurs C, Estrade A, Hanaire H, Ritz P. Impacts de la participation à un programme d’éducation thérapeutique avant chirurgie bariatrique sur le suivi postopératoire. NUTR CLIN METAB 2016. [DOI: 10.1016/j.nupar.2016.09.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
33
|
Barranger C, Marechal P, Bertrand M, Dube M, Heckel D, Joannes M. RNA internal control, a new tool for the rapid development of detection tools by real time PCR in outbreak situation. Application to the detection of Middle East Respiratory Syndrome human coronavirus. J Clin Virol 2016. [PMCID: PMC7130028 DOI: 10.1016/j.jcv.2016.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
34
|
Miguirditchian M, Bernier G, Pacary V, Balaguer C, Sorel C, Berlemont R, Fries B, Bertrand M, Camès B, Leydier A, Turgis R, Arrachart G, Pellet-Rostaing S, Mokhtari H. Development of a new solvent extraction process based on butyl-1-[N,N-bis(2-ethylhexyl)carbamoyl]nonyl phosphonic acid for the selective recovery of uranium(VI) from phosphoric acid. Solvent Extraction and Ion Exchange 2016. [DOI: 10.1080/07366299.2016.1169147] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Abstract
INTRODUCTION Anatomy is the cornerstone of medical education. Different teaching methods can be combined. This study was designed to evaluate the influence of students' drawing of the anatomical region before and after the dissection session on their memorization of the studied anatomical region. METHOD Four hundred and sixteen second-year medical students in the faculty of medicine of Damascus were included in this study during the 2013-2014 academic year. Students were randomly divided into three blinded groups. Two groups had to draw the anatomical region respectively before and after the dissection session, while the third group did not have to draw. The memorization of the region was evaluated twice, one and seven weeks after the course. Means were compared using a t-test. RESULTS Scores were significantly higher at 1 and 7 weeks tests in groups who were asked to draw either before or after the dissection compared to those who were not asked to draw. No statistical difference was found between the two groups who drew. CONCLUSION The authors recommend the use of drawing in teaching anatomy.
Collapse
Affiliation(s)
- B Alsaid
- Laboratory of Anatomy, Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Damascus, Fayez Mansour Street, Damascus, Syria.
| | - M Bertrand
- Laboratory of Anatomy and Learning through Simulation, Nîmes Faculty of Medicine, 30029 Nîmes, France
| |
Collapse
|
36
|
Haudebourg L, Seringe E, Aggoune M, Bertrand M, Boulot F, Astagneau P. A nosocomial hepatitis viral c transmission in an auto-dialysis center: risk factors using a root-causes analysis. Antimicrob Resist Infect Control 2015. [PMCID: PMC4475066 DOI: 10.1186/2047-2994-4-s1-p229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
37
|
Mojica-Rodríguez L, Bertrand M, Gaillard J, Muhr H, Plasari E, Auger F, Brackx E. Study on uranium peroxide precipitation in a continuous fluidized-bed reactor with mechanical stirring. Nuclear Engineering and Design 2015. [DOI: 10.1016/j.nucengdes.2015.07.058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
38
|
Danober L, Louis C, Rogez N, Thomas J, Dores GD, Gandon M, Hugot A, Beracochea D, Krazem A, Bertaina-AngladE V, Rimet D, Pillot T, Bertrand M, Fourquez J, Botez I, Lestage P. Pharmacological profile of S 76892, a new ligand at nicotinic α7-subtype receptors. Biochem Pharmacol 2015. [DOI: 10.1016/j.bcp.2015.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
39
|
Bellissen A, Bertrand M, Templier C, Lardenois E, Mortier L, Darras-Vercambre S. Maladie de Paget extra-mammaire secondaire multifocale. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
40
|
Danel Buhl N, Lescut D, Albert-Dunais V, Bertrand M, Bories C, Darmon P, De Luca A, Dennetière S, Fayemendy P, Jesus P, Petit A, Raynard B, Hennequin V. O07: Analyse rétrospective multicentrique du ratio NE/NP. NUTR CLIN METAB 2014. [DOI: 10.1016/s0985-0562(14)70583-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Bourgain C, Bertrand M, Seringe E. Les bactéries hautement résistantes émergentes en service d’hémodialyse et de néphrologie : pertinence des prélèvements systématiques. Nephrol Ther 2014. [DOI: 10.1016/j.nephro.2014.07.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Bertrand M, Brannemark R. Osseo-integration for rehabilitation of amputees. Ann Phys Rehabil Med 2014. [DOI: 10.1016/j.rehab.2014.03.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Bertrand M, Brannemark R. Ostéointégration pour la réhabilitation des amputés. Ann Phys Rehabil Med 2014. [DOI: 10.1016/j.rehab.2014.03.468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Hossard L, Philibert A, Bertrand M, Colnenne-David C, Debaeke P, Munier-Jolain N, Jeuffroy MH, Richard G, Makowski D. Effects of halving pesticide use on wheat production. Sci Rep 2014; 4:4405. [PMID: 24651597 PMCID: PMC3960944 DOI: 10.1038/srep04405] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 02/28/2014] [Indexed: 11/16/2022] Open
Abstract
Pesticides pose serious threats to both human health and the environment. In Europe, farmers are encouraged to reduce their use, and in France a recent environmental policy fixed a target of halving the pesticide use by 2018. Organic and integrated cropping systems have been proposed as possible solutions for reducing pesticide use, but the effect of reducing pesticide use on crop yield remains unclear. Here we use a set of cropping system experiments to quantify the yield losses resulting from a reduction of pesticide use for winter wheat in France. Our estimated yield losses resulting from a 50% reduction in pesticide use ranged from 5 to 13% of the yield obtained with the current pesticide use. At the scale of the whole country, these losses would decrease the French wheat production by about 2 to 3 millions of tons, which represent about 15% of the French wheat export.
Collapse
Affiliation(s)
- L. Hossard
- INRA, UMR211 Agronomie, F-78850 Thiverval-Grignon, France
- AgroParisTech, UMR Agronomie, F-78850 Thiverval-Grignon, France
| | - A. Philibert
- INRA, UMR211 Agronomie, F-78850 Thiverval-Grignon, France
- AgroParisTech, UMR Agronomie, F-78850 Thiverval-Grignon, France
| | - M. Bertrand
- INRA, UMR211 Agronomie, F-78850 Thiverval-Grignon, France
- AgroParisTech, UMR Agronomie, F-78850 Thiverval-Grignon, France
| | - C. Colnenne-David
- INRA, UMR211 Agronomie, F-78850 Thiverval-Grignon, France
- AgroParisTech, UMR Agronomie, F-78850 Thiverval-Grignon, France
| | - P. Debaeke
- INRA, UMR1248 AGIR, F-31320 Castanet-Tolosan, France
- Université de Toulouse, INPT, UMR AGIR, F-31029 Toulouse, France
| | - N. Munier-Jolain
- INRA, UMR1347 Agroecologie, F-21065 Dijon, France
- AgroSup Dijon, UMR Agroecologie, F-21065 Dijon, France
| | - M. H. Jeuffroy
- INRA, UMR211 Agronomie, F-78850 Thiverval-Grignon, France
- AgroParisTech, UMR Agronomie, F-78850 Thiverval-Grignon, France
| | - G. Richard
- INRA, UAR1155 Département Environnement et Agronomie, F-84914 Avignon, France
| | - D. Makowski
- INRA, UMR211 Agronomie, F-78850 Thiverval-Grignon, France
- AgroParisTech, UMR Agronomie, F-78850 Thiverval-Grignon, France
| |
Collapse
|
45
|
Bertrand M, Mailliez A, Vercambre S, Kotecki N, Mortier L, Bonneterre J. Abstract P3-09-15: Permanent chemotherapy induced alopecia in early breast cancer patients after (neo)adjuvant chemotherapy: Long term follow up. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-09-15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Chemotherapy-induced alopecia (CIA) persisting for more than six months after the end of chemotherapy is defined as permanent alopecia. Scalp cooling is proposed to reduce this distressing side-effect.We evaluated the prevalence and the risk factors of permanent CIA in breast cancer patients receiving (neo)adjuvant chemotherapy.
Patients and methods:
79 patients (pts) treated with (neo)adjuvant chemotherapy (fluorouracil, epirubicin, cyclophosphamide (FEC-100) and docetaxel) for early breast cancer at the Oscar Lambret Center between July 2005 and December 2007 were included in our study. Scalp cooling was used to all pts during chemotherapy. All patients underwent a clinical examination and photographs of the scalp five years after the end of chemotherapy. These images were analysed by two different physicians and patients were divided into two groups: alopecia (regardless of severity) and control. They were asked for the impact on their quality of life. Potential risk factors were collected.
Results:
26 pts (32.9%) had alopecia: minimal (21 pts), moderate (2 pts) or severe (3 pts). In alopecia group, pts were significantly older and more often postmenopausal than in the control group (p 0.0073 and 0.005, respectively). In multivariate analysis (age and menopause), menopause was identified as a significant risk factor for developing alopecia (OR = 4.136, 95% CI (1.482-11.54)). The presence of impaired quality of life was significantly higher in the group alopecia than in the control group (p = 0.00006). There was no significant difference on personal history, potentially alopeciant drug intake (include hormonotherapy) and depilation of the eyebrows between the two groups. Main hypotheses are irreversible toxicity on stem cells follicles hairs, endocrine disorders and earlier onset of androgenetic alopecia in genetically predisposed subjects.
Conclusion:
The risk of permanent alopecia induced by anthracyclins and taxans based chemotherapy should not be underestimated. Early breast cancer pts, especially if they are postmenopausal, have to be aware of this toxicity with major aesthetic and psychosocial consequences.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-09-15.
Collapse
Affiliation(s)
- M Bertrand
- Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France
| | - A Mailliez
- Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France
| | - S Vercambre
- Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France
| | - N Kotecki
- Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France
| | - L Mortier
- Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France
| | - J Bonneterre
- Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France
| |
Collapse
|
46
|
|
47
|
Mourad JJ, Brugts J, Bertrand M. Number needed to treat and reduction of outcomes with RAAS inhibitors. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht311.5963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
48
|
Bertrand M, Rouanet P, Mourregot A, Azar C, Carrere S, Gutowski M, Quenet F, Saint-Aubert B, Colombo P. 337. TransAnal Endoscopic Proctectomy (TAEP) – An innovative procedure for difficult resection of rectal tumors in men with narrow pelvis. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
49
|
Bertrand M, Alsaid B, Droupy S, Rouanet P, Colombo P, Prudhomme M. 175. Optimal surgical plans to perform total mesorectal excision, while ensuring nervous conservation – Clear-cut answers thanks to a 3D histological approach. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
50
|
Lalleman S, Bertrand M, Plasari E, Sorel C, Moisy P. Determination of the Bromley contributions to estimate the activity coefficient of neodymium electrolytes. Chem Eng Sci 2012. [DOI: 10.1016/j.ces.2012.02.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|